Clinical Trial Update: Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating autologous CMV-specific CD8+ T cells to treat CMV reactivation after allogeneic stem cell transplantation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• Autologous CMV-specific CD8+ T Cells

Snippet

Sponsor: Imperial College London | Conditions: CMV Reactivation, Allogeneic Stem Cell Transplantation | Phase 1, Phase 2 | Status: WITHDRAWN